Three Seasons Wealth LLC Purchases New Stake in Moderna, Inc. $MRNA

Posted by George Bondi on Jul 17th, 2026

Three Seasons Wealth LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 8,016 shares of the company’s stock, valued at approximately $407,000.

A number of other large investors have also added to or reduced their stakes in the company. New Mexico Educational Retirement Board increased its position in shares of Moderna by 1.9% in the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock valued at $463,000 after acquiring an additional 300 shares during the period. Cromwell Holdings LLC boosted its holdings in shares of Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares during the period. IFP Advisors Inc boosted its holdings in shares of Moderna by 5.4% during the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after purchasing an additional 348 shares during the period. Empowered Funds LLC grew its stake in shares of Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock worth $405,000 after purchasing an additional 353 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its stake in shares of Moderna by 16.9% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock worth $78,000 after purchasing an additional 382 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares in the company, valued at approximately $183,800.16. This represents a 70.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. This represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,088 shares of company stock valued at $6,193,713 in the last three months. Company insiders own 10.80% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $63.15 on Friday. Moderna, Inc. has a one year low of $22.28 and a one year high of $85.60. The company has a 50-day simple moving average of $57.72 and a two-hundred day simple moving average of $50.73. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The firm has a market capitalization of $25.06 billion, a PE ratio of -7.75 and a beta of 0.94.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The firm had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm’s revenue was up 260.2% on a year-over-year basis. During the same period in the prior year, the company posted ($2.52) EPS. On average, analysts anticipate that Moderna, Inc. will post -6.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Barclays boosted their price target on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Bank of America lifted their price objective on Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Morgan Stanley upped their target price on Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Finally, UBS Group restated a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Two research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $38.27.

Read Our Latest Report on Moderna

Moderna Company Profile

(Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.